Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-15 (Canceled)

Claim 16 (Currently Amended) A method of promoting growth of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof, said method comprising administering at least one promoter comprising Cofilin including comprising the amino acid sequence depicted by of SEQ ID NO: 1 as an active ingredient and promoting growth of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claims 17-18 (Canceled)

Claim 19 (Currently Amended) A method of expanding hematopoietic stem cells *ex vivo* comprising administering at least one promoter comprising Cofilin including comprising the amino acid sequence depicted by of SEQ ID NO: 1 to the hematopoietic stem cells, and expanding said hematopoietic stem cells *ex vivo*.

Claim 20 (Currently Amended) A method of treating diseases a disease that results from insufficient growth of hematopoietic stem cells and/or hematopoietic progenitors in a subject, comprising expanding hematopoietic stem cells and/or hematopoietic progenitors ex vivo by administering at least one promoter comprising Cofilin including comprising the amino acid sequence depicted by of SEQ ID NO: 1 to the hematopoietic stem cells and/or hematopoietic progenitors, and transplanting the said expanded hematopoietic stem cells and/or hematopoietic progenitors into said subject.

Claims 21-25 (Canceled)

Claim 26 (Previously Presented) The method of claim 16, 19 or 20, wherein the Cofilin is produced by a gene recombinant technique.

Claim 27 (Previously Presented) The method of claim 16, 19 or 20, wherein the Cofilin includes a sugar chain.

Claim 28 (Currently Amended) The method of claim 16, 19 or 20, wherein the promoter further includes a cytokine other than Cofilin said method further comprises administering a cytokine.

Claim 29 (Currently Amended) The method of claim 28, wherein said cytokine other-than Cofilin is interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10 and IL-11, granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), erythropoietin (EPO), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor-α (TGF-α), protease nexin I, protease nexin II, platelet derived growth factor (PDGF), cholinergic differentiation factor (CDF), leukocyte migration inhibitory factor (LIF), stem cell factor (SCF), flk-2/flt-3 ligand (FL), thrombopoietin (TPO), IL-6/soluble IL-6 receptor complex, Hyper IL-6 (fusion protein from IL-6 or soluble IL-6 receptor), or any combinations thereof.

Claim 30 (Currently Amended) The method of claim 28, wherein said cytokine other than Cofilin is IL-3.

Claim 31 (Currently Amended) The method of claim 28, wherein said cytokine other than Cofilin comprises stem cell factor (SCF), flk-2/flt-3 ligand (FL), or a combination thereof.

Claims 32-36 (Canceled)

Claim 37 (Previously Presented) The method of claim 16, 19 or 20, wherein the Cofilin is encoded by SEQ ID NO: 2.

Claim 38 (Currently Amended) The method of claim 20, wherein said promoter is for treating disease is panhematopenia or diseases that are a disease accompanied by hematopoietic hypofunction.

Claim 39 (Currently Amended) A method of promoting differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof, said method comprising administering at lease one promoter comprising Cofilin including comprising the amino acid sequence depicted by of SEQ ID NO: 1 and a cytokine other than Cofilin as active ingredients, and promoting differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 40 (Currently Amended) A method of treating diseases a disease that results from insufficient growth of hematopoietic stem cells and/or hematopoietic progenitors in a subject, comprising expanding hematopoietic stem cells and/or hematopoietic progenitors ex vivo by administering at lease one promoter comprising Cofilin including comprising the amino acid sequence depicted by of SEQ ID NO: 1 and a cytokine other than Cofilin as active ingredients to the hematopoietic stems cells and/or hematopoietic progenitors, and transplanting the said expanded hematopoietic stem cells and/or hematopoietic progenitors into said subject.

Claim 41 (Currently Amended) The method of claim 40, wherein said promoter is for treating disease is panhematopenia or diseases that are a disease accompanied by hematopoietic hypofunction.

Claim 42 (Previously Presented) The method of claim 39 or 40, wherein the Cofilin is produced by a gene recombinant technique.

Claim 43 (Previously Presented) The method of claim 39 or 40, wherein the Cofilin includes a sugar chain.

Claim 44 (Currently Amended) The method of claim 39 or 40, wherein said cytokine other than Cofilin is interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10 and IL-11, granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), erythropoietin (EPO), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor-α (TGF-α), protease nexin I, protease nexin II, platelet derived growth factor (PDGF), cholinergic

differentiation factor (CDF), leukocyte migration inhibitory factor (LIF), stem cell factor (SCF), flk-2/flt-3 ligand (FL), thrombopoietin (TPO), IL-6/soluble IL-6 receptor complex, Hyper IL-6 (fusion protein from IL-6 or soluble IL-6 receptor), or any combinations thereof.

Claim 45 (Currently Amended) The method of claim 39 or 40, wherein said cytokine other than Cofilin is IL-3.

Claim 46 (Currently Amended) The method of claim 39 or 40, wherein said cytokine other than Cofilin comprises stem cell factor (SCF), flk-2/flt-3 ligand (FL), or a combination thereof.

Claims 47-48 (Canceled)

Claim 49 (Previously Presented) The method of claim 39 or 40, wherein the Cofilin is encoded by SEQ ID NO: 2.

Claim 50 (New) The method of any one of claims 16, 19, 20, 39, or 40, said method comprising administering Cofilin protein of SEQ ID NO: 1.